Amgen’s Bkemv is the first interchangeable biosimilar to Soliris to treat certain rare diseases. The treatment of patients ...
Donanemab could be the second amyloid antibody drug approved to treat early-stage Alzheimer’s disease. The drug slowed ...
A panel of experts advising the Food and Drug Administration could on Monday recommend Eli Lilly’s experimental Alzheimer’s ...
The U.S. Food and Drug Administration has approved French drugmakers Ipsen and Genfit's drug to treat a chronic inflammatory ...
There isn’t a cure for Alzheimer’s disease, the most common form of dementia in the U.S., but a third treatment for the ...
The modest benefits of the treatment, donanemab, made by Eli Lilly, outweigh the risks, the panel concluded unanimously.
On June 6, the U.S. Food and Drug Administration (FDA) approved Geron's first drug, imetelstat (brand name Rytelo), to treat ...
The new weight-loss drug company emerged from stealth with big plans to take on obesity drugs like Wegovy and Zepbound.
The FDA has made two approvals this week: the first interchangeable biosimilar of Soliris and another indication for Breyanzi ...
President Joe Biden and former President Donald Trump have seemingly found one issue they can agree on: Drug costs are too high. Each is crediting himself with price-busting policy successes that ...
Amgen (NASDAQ:AMGN) today announced the presentation of data across its diverse portfolio and pipeline at the European Alliance of Associations for Rheumatology's (EULAR) 2024 Congress, June 12-15 in ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Ozempic and Wegovy (semaglutide for diabetes and weight loss, respectively) ...